Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
Status: Enrolling
Updated:  10/20/2017
St. Francis Cancer Center
mi
from
Beech Grove, IN
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
Status: Enrolling
Updated: 10/20/2017
St. Francis Cancer Center
mi
from
Beech Grove, IN
Click here to add this to my saved trials
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
Status: Enrolling
Updated:  10/20/2017
University of Louisville Brown Cancer Center
mi
from
Louisville, KY
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
Status: Enrolling
Updated: 10/20/2017
University of Louisville Brown Cancer Center
mi
from
Louisville, KY
Click here to add this to my saved trials
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
Status: Enrolling
Updated:  10/20/2017
Maine General Medical Center Harold Alfond Center for Cancer Care
mi
from
Waterville, ME
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
Status: Enrolling
Updated: 10/20/2017
Maine General Medical Center Harold Alfond Center for Cancer Care
mi
from
Waterville, ME
Click here to add this to my saved trials
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
Status: Enrolling
Updated:  10/20/2017
Johns Hopkins University
mi
from
Baltimore, MD
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
Status: Enrolling
Updated: 10/20/2017
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
Status: Enrolling
Updated:  10/20/2017
St. Louis University Medical Center
mi
from
Saint Louis, MO
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
Status: Enrolling
Updated: 10/20/2017
St. Louis University Medical Center
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
Status: Enrolling
Updated:  10/20/2017
The Cancer Center, Hackensack University Medical Center
mi
from
Hackensack, NJ
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
Status: Enrolling
Updated: 10/20/2017
The Cancer Center, Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
Status: Enrolling
Updated:  10/20/2017
North Shore LIJ Center for Advanced Medicine Monter Cancer Center
mi
from
Lake Success, NY
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
Status: Enrolling
Updated: 10/20/2017
North Shore LIJ Center for Advanced Medicine Monter Cancer Center
mi
from
Lake Success, NY
Click here to add this to my saved trials
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
Status: Enrolling
Updated:  10/20/2017
Weil Cornell Medical Center
mi
from
New York, NY
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
Status: Enrolling
Updated: 10/20/2017
Weil Cornell Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
Status: Enrolling
Updated:  10/20/2017
New York Medical College
mi
from
New York, NY
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
Status: Enrolling
Updated: 10/20/2017
New York Medical College
mi
from
New York, NY
Click here to add this to my saved trials
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
Status: Enrolling
Updated:  10/20/2017
Montefiore Medical Center
mi
from
The Bronx, NY
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
Status: Enrolling
Updated: 10/20/2017
Montefiore Medical Center
mi
from
The Bronx, NY
Click here to add this to my saved trials
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
Status: Enrolling
Updated:  10/20/2017
Blumenthal Cancer Center/Mecklenburg Medical Group
mi
from
Charlotte, NC
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
Status: Enrolling
Updated: 10/20/2017
Blumenthal Cancer Center/Mecklenburg Medical Group
mi
from
Charlotte, NC
Click here to add this to my saved trials
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
Status: Enrolling
Updated:  10/20/2017
Duke Comprehensive Cancer Center
mi
from
Durham, NC
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
Status: Enrolling
Updated: 10/20/2017
Duke Comprehensive Cancer Center
mi
from
Durham, NC
Click here to add this to my saved trials
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
Status: Enrolling
Updated:  10/20/2017
Jewish Hospital of Cincinatti
mi
from
Cincinnati, OH
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
Status: Enrolling
Updated: 10/20/2017
Jewish Hospital of Cincinatti
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
Status: Enrolling
Updated:  10/20/2017
Oregon Health and Science University
mi
from
Portland, OR
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
Status: Enrolling
Updated: 10/20/2017
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
Status: Enrolling
Updated:  10/20/2017
Oncology Hematology of Lehigh Valley
mi
from
Bethlehem, PA
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
Status: Enrolling
Updated: 10/20/2017
Oncology Hematology of Lehigh Valley
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
Status: Enrolling
Updated:  10/20/2017
Western Pennsylvania Hospital
mi
from
Pittsburgh, PA
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
Status: Enrolling
Updated: 10/20/2017
Western Pennsylvania Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
Status: Enrolling
Updated:  10/20/2017
UTMB Comprehensive Cancer Center
mi
from
Galveston, TX
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
Status: Enrolling
Updated: 10/20/2017
UTMB Comprehensive Cancer Center
mi
from
Galveston, TX
Click here to add this to my saved trials
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
Status: Enrolling
Updated:  10/20/2017
M.D. Anderson Cancer Center
mi
from
Houston, TX
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
Status: Enrolling
Updated: 10/20/2017
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
Status: Enrolling
Updated:  10/20/2017
Joe Arrington Cancer Center
mi
from
Lubbock, TX
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
Status: Enrolling
Updated: 10/20/2017
Joe Arrington Cancer Center
mi
from
Lubbock, TX
Click here to add this to my saved trials
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
Status: Enrolling
Updated:  10/20/2017
Texas Tech University Health Sciences Center
mi
from
Lubbock, TX
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
Status: Enrolling
Updated: 10/20/2017
Texas Tech University Health Sciences Center
mi
from
Lubbock, TX
Click here to add this to my saved trials
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
Status: Enrolling
Updated:  10/20/2017
Cancer Therapy and Research Center at The University of TX Health Science Center
mi
from
San Antonio, TX
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
Status: Enrolling
Updated: 10/20/2017
Cancer Therapy and Research Center at The University of TX Health Science Center
mi
from
San Antonio, TX
Click here to add this to my saved trials
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
Status: Enrolling
Updated:  10/20/2017
Intermountain LDS Hospital
mi
from
Salt Lake City, UT
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
Status: Enrolling
Updated: 10/20/2017
Intermountain LDS Hospital
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
Status: Enrolling
Updated:  10/20/2017
Medical College of Wisconsin
mi
from
Milwaukee, WI
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
Status: Enrolling
Updated: 10/20/2017
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
Status: Enrolling
Updated:  10/20/2017
Vancouver General Hospital/British Columbia Cancer Agency
mi
from
Vancouver,
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
Status: Enrolling
Updated: 10/20/2017
Vancouver General Hospital/British Columbia Cancer Agency
mi
from
Vancouver,
Click here to add this to my saved trials
Study of Carfilzomib in Combination w/Dexamethasone in Patients w/Newly Diagnosed Multiple Myeloma
An Open-label, Single-arm, Phase 1b/ 2 Study of Carfilzomib in Combination With Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
Status: Enrolling
Updated:  10/23/2017
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Study of Carfilzomib in Combination w/Dexamethasone in Patients w/Newly Diagnosed Multiple Myeloma
An Open-label, Single-arm, Phase 1b/ 2 Study of Carfilzomib in Combination With Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
Status: Enrolling
Updated: 10/23/2017
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients
An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients
Status: Enrolling
Updated:  10/23/2017
Franciscan Saint Francis Health
mi
from
Indianapolis, IN
An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients
An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients
Status: Enrolling
Updated: 10/23/2017
Franciscan Saint Francis Health
mi
from
Indianapolis, IN
Click here to add this to my saved trials
An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients
An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients
Status: Enrolling
Updated:  10/23/2017
University of Kansas Cancer Center
mi
from
Westwood, KA
An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients
An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients
Status: Enrolling
Updated: 10/23/2017
University of Kansas Cancer Center
mi
from
Westwood, KA
Click here to add this to my saved trials
An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients
An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients
Status: Enrolling
Updated:  10/23/2017
Oregon Health and Science University
mi
from
Portland, OR
An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients
An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients
Status: Enrolling
Updated: 10/23/2017
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients
An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients
Status: Enrolling
Updated:  10/23/2017
Medical University of South Carolina
mi
from
Charleston, SC
An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients
An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients
Status: Enrolling
Updated: 10/23/2017
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients
An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients
Status: Enrolling
Updated:  10/23/2017
Medical College of Wisconsin
mi
from
Milwaukee, WI
An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients
An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients
Status: Enrolling
Updated: 10/23/2017
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
A Non-Myeloablative Conditioning Regimen With Peri-Transplant Rituximab and the Transplantation of Hematopoietic Stem Cells From HLA-Compatible Related or Unrelated Donors in Patients With B Cell Lymphoid Malignancies
Status: Enrolling
Updated:  10/24/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
A Non-Myeloablative Conditioning Regimen With Peri-Transplant Rituximab and the Transplantation of Hematopoietic Stem Cells From HLA-Compatible Related or Unrelated Donors in Patients With B Cell Lymphoid Malignancies
Status: Enrolling
Updated: 10/24/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201)
Status: Enrolling
Updated:  10/24/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201)
Status: Enrolling
Updated: 10/24/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201)
Status: Enrolling
Updated:  10/24/2017
City of Hope National Medical Center
mi
from
Duarte, CA
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201)
Status: Enrolling
Updated: 10/24/2017
City of Hope National Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201)
Status: Enrolling
Updated:  10/24/2017
UCSD Cancer Center
mi
from
La Jolla, CA
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201)
Status: Enrolling
Updated: 10/24/2017
UCSD Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201)
Status: Enrolling
Updated:  10/24/2017
University of California at San Francisco
mi
from
San Francisco, CA
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201)
Status: Enrolling
Updated: 10/24/2017
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201)
Status: Enrolling
Updated:  10/24/2017
Stanford Hospital and Clinics
mi
from
Stanford, CA
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201)
Status: Enrolling
Updated: 10/24/2017
Stanford Hospital and Clinics
mi
from
Stanford, CA
Click here to add this to my saved trials
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201)
Status: Enrolling
Updated:  10/24/2017
University of Florida College of Medicine (Shands)
mi
from
Gainesville, FL
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201)
Status: Enrolling
Updated: 10/24/2017
University of Florida College of Medicine (Shands)
mi
from
Gainesville, FL
Click here to add this to my saved trials
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201)
Status: Enrolling
Updated:  10/24/2017
Emory University
mi
from
Atlanta, GA
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201)
Status: Enrolling
Updated: 10/24/2017
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201)
Status: Enrolling
Updated:  10/24/2017
Loyola University
mi
from
Maywood, IL
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201)
Status: Enrolling
Updated: 10/24/2017
Loyola University
mi
from
Maywood, IL
Click here to add this to my saved trials
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201)
Status: Enrolling
Updated:  10/24/2017
IBMT (Indiana Blood and Marrow Transplant) at St Francis Franciscan Health
mi
from
Indianapolis, IN
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201)
Status: Enrolling
Updated: 10/24/2017
IBMT (Indiana Blood and Marrow Transplant) at St Francis Franciscan Health
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201)
Status: Enrolling
Updated:  10/24/2017
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201)
Status: Enrolling
Updated: 10/24/2017
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201)
Status: Enrolling
Updated:  10/24/2017
University of Kansas Hospital
mi
from
Kansas City, KA
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201)
Status: Enrolling
Updated: 10/24/2017
University of Kansas Hospital
mi
from
Kansas City, KA
Click here to add this to my saved trials
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201)
Status: Enrolling
Updated:  10/24/2017
University of Maryland
mi
from
Baltimore, MD
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201)
Status: Enrolling
Updated: 10/24/2017
University of Maryland
mi
from
Baltimore, MD
Click here to add this to my saved trials
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201)
Status: Enrolling
Updated:  10/24/2017
DFCI/Brigham & Women's
mi
from
Boston, MA
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201)
Status: Enrolling
Updated: 10/24/2017
DFCI/Brigham & Women's
mi
from
Boston, MA
Click here to add this to my saved trials
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201)
Status: Enrolling
Updated:  10/24/2017
University of Michigan Medical Center
mi
from
Ann Arbor, MI
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201)
Status: Enrolling
Updated: 10/24/2017
University of Michigan Medical Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201)
Status: Enrolling
Updated:  10/24/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201)
Status: Enrolling
Updated: 10/24/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201)
Status: Enrolling
Updated:  10/24/2017
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201)
Status: Enrolling
Updated: 10/24/2017
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Click here to add this to my saved trials
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201)
Status: Enrolling
Updated:  10/24/2017
Washington University/ Barnes-Jewish Hospital
mi
from
Saint Louis, MO
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201)
Status: Enrolling
Updated: 10/24/2017
Washington University/ Barnes-Jewish Hospital
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201)
Status: Enrolling
Updated:  10/24/2017
Washington University/St. Louis Children's Hospital
mi
from
Saint Louis, MO
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201)
Status: Enrolling
Updated: 10/24/2017
Washington University/St. Louis Children's Hospital
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201)
Status: Enrolling
Updated:  10/24/2017
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201)
Status: Enrolling
Updated: 10/24/2017
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials